<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450073</url>
  </required_header>
  <id_info>
    <org_study_id>Cystic Fibrosis Vitamin D</org_study_id>
    <nct_id>NCT00450073</nct_id>
  </id_info>
  <brief_title>Improving Vitamin D Status In Cystic Fibrosis</brief_title>
  <official_title>Desktop Tanning Unit to Improve Vitamin D Status in Patients With Cystic Fibrosis and Short Bowel Syndrome: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atlanta VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atlanta VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish an effective method to correct vitamin D deficiency
      in subjects with cystic fibrosis. The investigators will examine cholecalciferol,
      ergocalciferol and UV light.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis of this study: Our hypothesis is that other methods such as cholecalciferol
      replacement and/or low dose ultraviolet radiation to the skin may be more effective in
      raising serum 25-hydroxyvitamin D levels than conventional ergocalciferol therapy.

      Experimental strategy: We will conduct a prospective randomized trail to determine which
      recommended vitamin D therapy (tanning device, cholecalciferol or ergocalciferol) is
      effective in maintaining or improving vitamin D status during the winter months. We will
      recruit CF patients according to the following inclusion and exclusion criteria:

      Inclusion: Subjects seen initially at the Emory CF center between the months of September and
      December, age &gt;16, both males and females, confirmed cystic fibrosis by genetic testing or
      sweat testing, FEV1 &gt;40%.

      Exclusion: History of lung transplant or awaiting lung transplantation, current
      hospitalization or greater than 6 hospitalizations/year, history of malignancy, renal disease
      (calculated GFR &lt;50% reduced from normal), liver disease (AST or AST &gt; 3 times upper limit of
      normal), greater than 10 mg of prednisone or equivalent, hypercalcemia, history of easily
      burned skin after sunlight exposure, taking medications with may cause photosensitivity,
      history of skin cancer or multiple moles or family history of skin cancer, moderate to severe
      vitamin D deficiency (25(OH)D ≤ 15 ng/ml).

      Physicians at the Emory CF center will be informed about the study. The primary CF doctor of
      the subject will refer the individual to one of the study investigators for potential
      recruitment. The principal investigator or co-investigator will meet with the prospective
      subject to discuss the details of the study. If the subject agrees to participate, they will
      sign an informed consent form. The subject will provide a blood specimen at the screening
      visit to determine eligibility for the study including 25-hydroxyvitamin D. If the subject's
      25(OH)D level is ≤15 ng/ml (moderate vitamin D deficiency), the subject will be excluded from
      the study. We have decided to exclude those moderately to severely deficient patients for
      ethical reasons since these subjects may require more aggressive medical management in
      correction of vitamin D status.

      The subject will then be randomized to either ergocalciferol 50,000 IU once a a week for 12
      weeks, cholecalciferol 50,000 IU once a week for 12 weeks, or use of a portable tanning
      device 5 times a week for 12 weeks. The blood sample obtained for screening will be used to
      determine baseline 25(OH)D, parathyroid hormone (PTH). This assignment can not be blinded for
      obvious reasons. Subjects assigned to cholecalciferol or ergocalciferol will be instructed on
      how to take the pill three times a week. The subjects assigned to the portable tanning
      machine will be given instructions on how to operate the device.

      All subjects will complete a baseline three day food diary to determine daily calcium and
      vitamin D intake levels. Those subjects already taking calcium supplements will be instructed
      to take no more than 1500 mg of calcium a day. Those subjects already taking multivitamin
      supplements will be limited to no more than 800 IU of vitamin D daily. Subjects will be
      allowed to continue with their usual diet; however, they should limit the number of milk
      servings to no more than 3 servings a day. Subjects will also be instructed not to travel to
      sunny climates or visit tanning salons during the study. No restrictions will be made in
      regards to outdoor activities since minimal vitamin D is made during the winter months.
      Subjects will return to the CF center 12 weeks after the randomization for repeat blood tests
      for 25(OH)D and PTH. Every two weeks, our research coordinator will call the subject to
      discuss compliance with the assigned therapy. In particular, those subjects assigned to pills
      will be reminded to take the pills weekly. Those subjects assigned to UV light will be asked
      questions regarding presence of skin erythema, photosensitivity, evidence of tanning and any
      other potential side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25-hydroxyvitamin D</measure>
    <time_frame>12 weeks</time_frame>
    <description>This is a marker of vitamin D status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone, Serum C-telopeptide, Osteocalcin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3=cholecalciferol 50,000 IU weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunlamp</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ergocalciferol (vitamin D2)</intervention_name>
    <description>50,000 IU weekly</description>
    <arm_group_label>vitamin D2</arm_group_label>
    <other_name>D2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sperti Del Sol Lamp</intervention_name>
    <description>5 times a week for 12 weeks</description>
    <arm_group_label>Sunlamp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>50,000 IU weekly</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects seen initially at the Emory CF center between the months of September and
             December

          -  Age &gt; 16, both males and females, confirmed cystic fibrosis by genetic testing or
             sweat testing, FEV1 &gt; 40%.

        Exclusion Criteria:

          -  History of lung transplant or awaiting lung transplantation

          -  Current hospitalization or greater than 6 hospitalizations/year

          -  History of malignancy, renal disease (calculated GFR &lt; 50% reduced from normal), liver
             disease (AST or AST &gt; 3 times upper limit of normal), greater than 10 mg of prednisone
             or equivalent, hypercalcemia

          -  History of easily burned skin after sunlight exposure, taking medications with may
             cause photosensitivity

          -  History of skin cancer or multiple moles or family history of skin cancer

          -  Moderate to severe vitamin D deficiency (25(OH)D ≤ 15 ng/ml).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vin Tangpricha, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory CF Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grossmann RE, Zughaier SM, Liu S, Lyles RH, Tangpricha V. Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation. Eur J Clin Nutr. 2012 Sep;66(9):1072-4. doi: 10.1038/ejcn.2012.82. Epub 2012 Jul 18.</citation>
    <PMID>22805498</PMID>
  </results_reference>
  <results_reference>
    <citation>Grossmann RE, Zughaier SM, Kumari M, Seydafkan S, Lyles RH, Liu S, Sueblinvong V, Schechter MS, Stecenko AA, Ziegler TR, Tangpricha V. Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: A randomized, controlled trial. Dermatoendocrinol. 2012 Apr 1;4(2):191-7. doi: 10.4161/derm.20332.</citation>
    <PMID>22928076</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2007</study_first_submitted>
  <study_first_submitted_qc>March 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2007</study_first_posted>
  <results_first_submitted>January 28, 2013</results_first_submitted>
  <results_first_submitted_qc>January 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2014</results_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atlanta VA Medical Center</investigator_affiliation>
    <investigator_full_name>Vin Tangpricha</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Please see full manuscript</recruitment_details>
      <pre_assignment_details>Please see full manuscript</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3</title>
          <description>vitamin D3 50,000 IU weekly</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D2</title>
          <description>vitamin D2 50,000 IU weekly</description>
        </group>
        <group group_id="P3">
          <title>Sunlamp</title>
          <description>Use of a sunlamp 5 times a week for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3</title>
          <description>vitamin D3 50,000 IU weekly</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D2</title>
          <description>vitamin D2 50,000 IU weekly</description>
        </group>
        <group group_id="B3">
          <title>Sunlamp</title>
          <description>Use of a sunlamp 5 times a week for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="12.5"/>
                    <measurement group_id="B2" value="27.9" spread="11.9"/>
                    <measurement group_id="B3" value="33.3" spread="15.7"/>
                    <measurement group_id="B4" value="32.1" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>25-hydroxyvitamin D</title>
        <description>This is a marker of vitamin D status</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>vitamin D3 50,000 IU weekly</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D2</title>
            <description>vitamin D2 50,000 IU weekly</description>
          </group>
          <group group_id="O3">
            <title>Sunlamp</title>
            <description>Weekly use of a sunlamp</description>
          </group>
        </group_list>
        <measure>
          <title>25-hydroxyvitamin D</title>
          <description>This is a marker of vitamin D status</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="10.3"/>
                    <measurement group_id="O2" value="24.4" spread="10.2"/>
                    <measurement group_id="O3" value="28.2" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parathyroid Hormone, Serum C-telopeptide, Osteocalcin</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3</title>
          <description>vitamin D3 50,000 IU weekly</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D2</title>
          <description>vitamin D2 50,000 IU weekly</description>
        </group>
        <group group_id="E3">
          <title>Sunlamp</title>
          <description>Weekly use of a sunlamp</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vin Tangpricha</name_or_title>
      <organization>Emory University</organization>
      <phone>4047277254</phone>
      <email>vin.tangpricha@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

